Haemophagocytic lymphohistiocytosis – Life with Disease

Go back

Haemophagocytic lymphohistiocytosis is a rare condition in which the immune system, instead of protecting the body, begins to attack it from within, causing severe inflammation and damage to multiple organs. Without quick recognition and proper treatment, this condition can rapidly become life-threatening, making early diagnosis absolutely crucial for survival.

Prognosis

Understanding what lies ahead when someone is diagnosed with haemophagocytic lymphohistiocytosis can be deeply unsettling, but knowing the reality helps families and patients prepare emotionally and practically. This condition presents one of the most serious challenges in medicine because without treatment, it progresses very rapidly. The outlook depends heavily on whether the disease is caught early and how quickly treatment begins.[1]

For those with the primary, inherited form of the disease, the prognosis without treatment is particularly grave. If the condition is not detected and addressed, primary haemophagocytic lymphohistiocytosis, or HLH, is usually fatal within just a few months of symptom onset. Studies have shown that the median survival can be as low as two months when the disease is left untreated.[6][3]

Even when treatment is started, the journey remains difficult. Statistics show that mortality rates can reach between 20 percent and 30 percent within the first two months after diagnosis, highlighting how dangerous delays in recognizing the condition can be.[6] The statistics improve significantly when treatment begins early and aggressively. For children diagnosed quickly and accurately at specialized centers equipped to manage this complicated disease, a cure becomes possible.[8]

The type of HLH a person has also influences the outlook. Those with secondary HLH, which develops in response to triggers like infections or cancer, may have a better prognosis if the condition is detected promptly and treated aggressively compared to those with the familial form.[3] However, even with aggressive treatment, some patients with primary disease may have a prognosis of only a few years unless a bone marrow transplant, also called hematopoietic stem cell transplantation, can be successfully performed.[3]

For patients with familial HLH who remain stable after initial therapy, continuing with a bone marrow transplant offers the best chance for long-term survival. When a suitable donor can be found and the patient’s condition is stable enough to proceed, transplantation can be life-saving.[9] Some patients have gone on to celebrate significant milestones, such as 10-year transplant anniversaries, and live completely normal lives again.[14]

⚠️ Important
Early diagnosis is critical for survival in haemophagocytic lymphohistiocytosis. Because the condition can progress within weeks or even days, any unexplained fever that doesn’t respond to antibiotics, combined with other warning signs like enlarged liver or spleen, unusual rashes, or severe fatigue, should prompt immediate medical evaluation. The difference between life and death often comes down to how quickly the condition is recognized and treatment begins.

Natural Progression

When haemophagocytic lymphohistiocytosis is not treated, the disease follows a devastating and rapid course. The immune system’s abnormal overactivity creates a cascade of problems throughout the body that worsen with each passing day. Understanding how the disease naturally progresses helps explain why treatment cannot be delayed.

The condition begins when certain white blood cells, specifically histiocytes and lymphocytes, become overactive. Instead of performing their normal protective functions, these cells begin attacking the body’s own tissues. They overproduce chemical messengers called cytokines, leading to what doctors call a “cytokine storm.” This massive release of inflammatory signals creates widespread inflammation throughout the body.[3]

As the disease progresses untreated, these overactive cells start attacking blood cells and bone marrow. They also damage the spleen, liver, lymph nodes, skin, and even the brain. The destruction of blood cells leads to dangerous shortages. Red blood cells are destroyed, causing anemia, which makes patients feel weak and tired. Platelets are consumed, leading to thrombocytopenia, which means the blood cannot clot properly and patients bruise easily or bleed spontaneously.[4]

The liver and spleen enlarge as they become overwhelmed by the disease process. This enlargement, called hepatomegaly and splenomegaly, can become visible as the abdomen swells. The liver may begin to fail, causing yellowing of the skin and eyes, a condition known as jaundice.[4]

Without intervention, multiple organ systems begin to fail. The inflammation affects the lungs, making breathing increasingly difficult. Brain involvement can cause seizures, confusion, loss of coordination, changes in mental status, and even coma. The bone marrow’s inability to produce new blood cells leaves the body defenseless against infections and unable to deliver oxygen to tissues.[2][4]

The speed at which this progression occurs varies between individuals, but for many, especially infants and young children with the familial form, deterioration happens within weeks or months of the first symptoms appearing. About 70 percent of children with primary HLH develop symptoms in the first year of life.[1][11]

Possible Complications

Haemophagocytic lymphohistiocytosis can lead to numerous serious complications that affect nearly every system in the body. These complications represent the most severe manifestations of the disease and require immediate medical attention. Even with treatment, some of these complications can develop, making close monitoring essential.

One of the most dangerous complications is liver failure. As the overactive immune cells attack the liver, this vital organ loses its ability to perform essential functions like filtering toxins from the blood, producing proteins needed for blood clotting, and processing nutrients. Liver failure can progress rapidly and may become irreversible without transplantation.[4]

Respiratory complications develop when the inflammation affects the lungs. Patients may experience severe breathing problems, called dyspnea, which can progress to complete respiratory failure requiring mechanical ventilation. The lungs may fill with fluid or become damaged by the inflammatory process, making it impossible for the body to get enough oxygen.[1]

The brain and nervous system are particularly vulnerable to damage in HLH. Neurological complications can include seizures that are difficult to control, inflammation of the brain tissue itself, bleeding into the eyes called retinal hemorrhages, loss of coordination, paralysis affecting one side of the body, and progressive decline in consciousness leading to coma.[1][9]

Bleeding complications arise from the severe shortage of platelets and the consumption of clotting factors. Patients may experience spontaneous bleeding from the gums that can result in tooth loss, nosebleeds that are difficult to stop, bleeding into the skin causing widespread bruising, or more seriously, internal bleeding into vital organs or the brain.[9]

The bone marrow’s failure leads to a condition called pancytopenia, where all types of blood cells drop to dangerously low levels. This leaves patients vulnerable to life-threatening infections because they lack white blood cells to fight bacteria and viruses. Without red blood cells, tissues throughout the body become starved for oxygen. The absence of platelets means any injury, no matter how minor, can lead to uncontrolled bleeding.[9]

Multi-organ failure represents the ultimate complication when several organ systems collapse simultaneously. The heart may weaken and fail to pump blood effectively. The kidneys may stop filtering waste products from the blood. The digestive system may shut down. When multiple organs fail together, survival becomes extremely unlikely even with intensive medical support.[2]

Some complications can develop even during treatment. The powerful medications and chemotherapy used to control the overactive immune system can themselves cause side effects and organ damage. Infections can develop because the treatments suppress the immune system. Patients undergoing bone marrow transplantation face additional risks including rejection of the transplant, infections, and graft-versus-host disease, where the donated immune cells attack the patient’s body.[9]

Impact on Daily Life

Living with haemophagocytic lymphohistiocytosis transforms every aspect of daily existence for patients and their families. The disease doesn’t just affect physical health; it reaches into emotional wellbeing, family dynamics, school or work life, and even simple pleasures that healthy people take for granted.

The physical limitations imposed by HLH are profound, especially during active disease. The severe fatigue that accompanies anemia makes even basic activities exhausting. A child who once ran and played may lack the energy to walk across a room. Adults may find themselves unable to work or care for their families. The weakness, dizziness, and lightheadedness that come with low blood counts make it unsafe to drive, climb stairs, or do anything that requires steady balance and strength.[1]

Frequent medical appointments consume enormous amounts of time and energy. Patients with HLH require intensive monitoring with regular blood tests, imaging studies, and visits to specialists. Hospital stays can last weeks or months, particularly during initial treatment or if complications develop. For children, this means missing school, falling behind academically, and losing connection with friends. For adults, prolonged absences from work can threaten employment and financial stability.[14]

The emotional and psychological impact can be overwhelming. Living with a rare, life-threatening disease creates anxiety and fear. Young children may not understand why they feel so sick or why they must endure painful tests and treatments. Adolescents and teenagers struggle with feeling different from their peers at a time when fitting in matters immensely. Many patients, regardless of age, experience sadness, depression, and anger about their situation. The irritability that can come from the disease itself adds another layer of emotional difficulty.[1]

Social isolation becomes a significant problem. During treatment, patients must often avoid crowded places and limit contact with others to reduce infection risk. Children miss birthday parties, school events, and sports activities. Adults find themselves withdrawing from social gatherings and community involvement. The visible signs of illness, such as pale skin, jaundice, rashes, or hair loss from chemotherapy, can make patients self-conscious about their appearance.[1]

Family life revolves around managing the illness. Parents of children with HLH often must take extended leave from work or quit jobs entirely to provide care. Siblings may feel neglected as attention focuses on the sick child. Financial pressures mount from medical bills, travel costs to specialized treatment centers, and lost income. Family members experience their own emotional strain, worry, and exhaustion from the demands of caregiving.[14]

For those who survive and achieve remission or cure through transplantation, the journey toward normal life continues long after treatment ends. Recovery takes time, and patients must gradually rebuild their strength and stamina. Some may face long-term effects from the disease or its treatment that require ongoing management. However, many patients do eventually return to full, active lives. They go back to school, resume hobbies and sports, return to work, and reconnect with friends and family. The key is patience and taking recovery one step at a time.[14]

⚠️ Important
Mental health support is crucial for both patients and families dealing with haemophagocytic lymphohistiocytosis. The emotional burden of living with a rare, life-threatening disease should never be underestimated. Seeking help from counselors, psychologists, or support groups is not a sign of weakness but an important part of comprehensive care that can significantly improve quality of life during and after treatment.

Support for Family

When a family member receives a diagnosis of haemophagocytic lymphohistiocytosis, the entire family embarks on a difficult journey together. Understanding what to expect and how to support the patient through potential clinical trial participation becomes an important consideration, as these studies may offer access to newer treatments while also contributing to medical knowledge that could help future patients.

Families should first understand that clinical trials for HLH aim to test new treatments or approaches that might be more effective or cause fewer side effects than current standard therapies. Because HLH is so rare, with primary HLH occurring in only about 1 in 50,000 births worldwide, clinical trials are particularly important for advancing treatment options.[1][3] Research studies help doctors understand the disease better, identify which patients might benefit most from specific treatments, and develop approaches that target the excessive immune activation more precisely.

Families can help patients consider clinical trial participation by first researching what trials are available. Many specialized centers that treat HLH, such as major children’s hospitals and academic medical centers, conduct clinical trials. Some hospitals have dedicated clinical trial coordinators or registries that families can contact to learn about current studies. The INTO-HLH Registry, for example, is a collaborative effort aimed at advancing knowledge about HLH by collecting data from patients. Participating in such registries helps doctors better diagnose and manage HLH and may improve treatment outcomes for future patients.[18]

When exploring clinical trial options, families should ask detailed questions about what participation involves. They need to understand the purpose of the study, what treatments or procedures will be used, how the trial treatment differs from standard care, what the potential risks and benefits are, how long participation will last, and whether travel to specific medical centers will be required. Understanding these details helps families make informed decisions about whether a particular trial is right for their situation.

Relatives can provide crucial practical support in preparing for trial participation. This includes organizing medical records, gathering family medical history (particularly important for genetic forms of HLH), keeping detailed notes about symptoms and their timeline, photographing visible symptoms like rashes or bruising, and coordinating transportation and housing if treatment occurs far from home. Many families find that creating a binder or digital folder with all medical information keeps everything organized and accessible.

The emotional support that family members provide cannot be overstated. Participating in a clinical trial can feel frightening, especially when dealing with a life-threatening disease. Family members help by attending medical appointments, asking questions the patient might not think of, taking notes during discussions with doctors, providing comfort during difficult procedures, and maintaining hope during setbacks. For children with HLH, parents and siblings can help by maintaining as much normalcy as possible, bringing favorite toys or items from home during hospital stays, and helping children understand what’s happening in age-appropriate ways.[14]

Families should also recognize that they need support too. Caring for someone with HLH is exhausting physically, emotionally, and financially. Connecting with other families who have experienced HLH through support groups or online communities can provide invaluable perspective and practical advice. Social workers at treatment centers can help families access financial assistance programs, find temporary housing near hospitals, and connect with community resources. Some organizations offer support specifically for families dealing with rare immune disorders.

Finally, families play a vital role in being advocates for their loved ones. Because HLH is so rare, many healthcare providers outside specialized centers have limited experience with the condition. Family members who educate themselves about HLH can help ensure that symptoms are taken seriously, that concerning changes are promptly reported to the medical team, and that the patient receives coordinated care from providers who understand this complex disease. This advocacy can quite literally save lives by preventing delays in diagnosis or treatment.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Emapalumab – An antibody treatment that targets interferon-gamma, indicated for primary HLH in adults and children with refractory, recurrent, or progressive disease or who are intolerant to conventional HLH therapy
  • Etoposide – A chemotherapy agent used as part of the initial treatment regimen to suppress the overactive immune system
  • Dexamethasone – A corticosteroid medication used to reduce inflammation and suppress immune system activity in HLH treatment
  • Cyclosporine – An immunosuppressant medication that may be added to the initial treatment regimen or used during continuation therapy

Ongoing Clinical Trials on Haemophagocytic lymphohistiocytosis

  • A study of ruxolitinib as first treatment for children with haemophagocytic lymphohistiocytosis (HLH)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study on Etoposide for Patients with Severe Hemophagocytic Lymphohistiocytosis in Intensive Care

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Gene Therapy Study for Familial Hemophagocytic Lymphohistiocytosis Using MUNC-CD34 and MUNC-T3 in Patients with UNC13D Gene Mutations

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still’s Disease or Systemic Lupus Erythematosus

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Italy The Netherlands

References

https://my.clevelandclinic.org/health/diseases/24292-hemophagocytic-lymphohistiocytosis

https://www.ncbi.nlm.nih.gov/books/NBK557776/

https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/hemophagocytic-lymphohistiocytosis-hlh

https://www.cincinnatichildrens.org/health/h/hlh

https://www.dana-farber.org/cancer-care/types/childhood-hemophagocytic-lymphohistiocytosis

https://www.sobi.com/en/haemophagocytic-lymphohistiocytosis-hlh

https://en.wikipedia.org/wiki/Hemophagocytic_lymphohistiocytosis

https://www.chop.edu/conditions-diseases/hemophagocytic-lymphohistiocytosis-hlh

https://emedicine.medscape.com/article/986458-overview

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x

https://pmc.ncbi.nlm.nih.gov/articles/PMC6785811/

https://pubmed.ncbi.nlm.nih.gov/36206094/

https://www.chop.edu/conditions-diseases/hemophagocytic-lymphohistiocytosis-hlh

https://www.cincinnatichildrens.org/service/h/hlh/patient-stories/hannah

https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/hemophagocytic-lymphohistiocytosis-hlh

https://my.clevelandclinic.org/health/diseases/24292-hemophagocytic-lymphohistiocytosis

https://www.chop.edu/conditions-diseases/hemophagocytic-lymphohistiocytosis-hlh/resources?page=0

https://hlhregistry.org/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3204727/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://pmc.ncbi.nlm.nih.gov/articles/PMC6558629/

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

Is haemophagocytic lymphohistiocytosis contagious?

No, HLH is not contagious and cannot be spread from person to person. The primary form is caused by inherited genetic mutations, while the secondary form is triggered by the body’s abnormal response to infections, cancer, or autoimmune diseases, not by the triggering condition itself being transmitted.

Can adults develop HLH or is it only a childhood disease?

While HLH most commonly affects infants and children, adults can also develop the condition. Secondary HLH typically occurs in adulthood, often triggered by infections, malignancies, or autoimmune conditions. Some studies suggest the average age of onset for secondary HLH is around 50 years, though it can appear at any age.

How quickly does HLH progress?

HLH can progress very rapidly, with some cases deteriorating within weeks or even days of symptom onset. Without treatment, the median survival can be as low as two months. This is why immediate medical attention for suspicious symptoms is critical for survival.

What triggers secondary HLH to develop?

Secondary HLH is most commonly triggered by viral infections, particularly Epstein-Barr virus, but can also be caused by other infections, cancers (especially blood cancers), autoimmune conditions, certain medications, or transplants. Most people who develop secondary HLH likely have some genetic predisposition combined with an environmental trigger.

If my child has primary HLH, will my other children develop it too?

Familial HLH is an autosomal recessive disease, meaning each sibling of a child with familial HLH has a 25 percent chance of developing the disease, a 50 percent chance of carrying the defective gene without symptoms, and a 25 percent chance of neither having the disease nor carrying the gene. Genetic counseling and testing can help families understand their specific situation.

🎯 Key takeaways

  • HLH creates a “cytokine storm” where the immune system’s own cells attack the body instead of protecting it, causing rapid multi-organ damage
  • Without treatment, HLH is usually fatal within months, but early diagnosis and aggressive treatment can save lives and even lead to complete cure
  • The condition is often misdiagnosed because its initial symptoms—fever, enlarged organs, rash—look like many other common illnesses
  • About 70 percent of children with primary HLH develop symptoms in their first year of life, making early recognition crucial
  • Bone marrow transplantation offers the best chance for long-term survival in familial HLH, with some patients celebrating 10-year anniversaries and living completely normal lives
  • Families play a vital role in recognizing symptoms, advocating for proper diagnosis, supporting clinical trial participation, and maintaining hope through difficult treatment
  • The disease affects every aspect of daily life—physical abilities, emotional wellbeing, family dynamics, school, work, and social connections—making comprehensive support essential
  • Delays in diagnosis can mean the difference between life and death, with mortality rates of 20 to 30 percent in the first two months after diagnosis